X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

IKT

Closed

Inhibikase Therapeutics inc

1.95
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.95
Day's Range: 1.82 - 1.97
Send
When Written:
 
0.612
Inhibikase Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing small molecule drugs to treat infectious diseases, neurological disorders, and cancer. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase's lead drug candidate, IkT-148009, is being developed for the treatment of Parkinson's disease and is currently in Phase 1 clinical trials. The company's other drug candidates include IkT-001Pro, which is being developed for the treatment of tuberculosis, and IkT-001Plus, which is being developed for the treatment of COVID-19. Inhibikase's drug development platform is based on its proprietary technology, which enables the discovery and development of small molecule drugs that target protein kinases.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X